The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.
Geoffrey Shapiro
Research Funding - Cyclacel
Eunice Lee Kwak
Research Funding - Cyclacel
James M. Cleary
No relevant relationships to disclose
Sara Tolaney
No relevant relationships to disclose
Leena Gandhi
No relevant relationships to disclose
Jeffrey W. Clark
No relevant relationships to disclose
Andrew Wolanski
No relevant relationships to disclose
Sheelagh Frame
Employment or Leadership Position - Cyclacel
Stock Ownership - Cybracel
Scott J. Rodig
No relevant relationships to disclose
Judy H. Chiao
Employment or Leadership Position - Cyclacel
Stock Ownership - Cyclacel